Boardroom Alpha
Start trial
10-K primary document
BCAB · Annual Report (Form 10-K) · Filed March 31, 2026

Bioatla Inc — 10-K exhibit

bcab-ex10_37.htm
Bioatla Inc on Boardroom Alpha
EX-10.37

Exhibit 10.37

 

Retention Bonus Agreement

 

This Retention Bonus Agreement (“Agreement”) outlines a retention bonus arrangement between BioAtla, Inc. (the “Company”) and Jay Short, effective March 20, 2026.

 

Overview

 

We’re offering you an opportunity to earn a retention bonus tied to key milestones, in recognition of your contributions and to support continued success in important financial goals.

 

Total Bonus

 

You’re eligible to earn up to a total of $352,714 to $529,070 in a cash retention bonus payment. This is not guaranteed compensation, and it must be earned as described below.

 

How It’s Earned

 

The bonus is tied to the Company’s achievement of the milestones set forth on Exhibit A hereto.

 

If a milestone is achieved ±20% of the target, the applicable bonus for that milestone will be adjusted on a straight-line basis up to 20% below and 20% above the target bonus.

 

Results below -20% will earn no bonus for that milestone. Results above +20% will be capped at 120% of the milestone target. The Company will determine, in its sole discretion, whether and to what extent a milestone has been achieved and the final calculated result and payout, if any.

 

The retention bonus is earned if and when the applicable milestone is met and the Company certifies payout.

 

Payment Timing

 

•
Payment will be made within 30 days after the milestone is achieved and certified.
•
You need to be actively employed and in good standing at the time the retention bonus is paid in order to earn the applicable retention bonus.
•
Any retention bonus that may be earned under this Agreement shall not be subject to, or covered by, your Severance Agreement with BioAtla, LLC dated July 1, 2018.

 

Taxes

 

All payments will go through payroll and have standard tax withholdings.

 

 

 

At-Will Employment

 

This doesn’t change your at-will employment status. Either you or the company can end employment at any time.

 

Confidentiality

 

Please keep the details of this bonus arrangement confidential unless required by law.

 

Entire Agreement

 

This Agreement constitutes the entire understanding between the parties regarding any retention bonuses that may be earned and supersedes all prior discussions or agreements on this subject.

 

 

If you agree, please sign below.

BioAtla, Inc.

By: /s/ Christian Vasquez
Name: Christian Vasquez
Title: Chief Financial Officer
Date: 03/24/2026

 

Jay Short, Ph.D.

Signature: /s/ Jay Short
Date: 03/24/2026

 

Exhibit A

Milestones

 

 

 

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer